BMC G3 BPAP and PAP Link – A Digital Leap in Healthcare

BMC Medical has established itself as one of the most trusted brands in respiratory care. Since its founding in Beijing in 2001, the company has remained committed to helping people breathe easier and sleep better. Today, BMC operates in over 100 countries, developing devices that are shaping the future of sleep medicine.

At the 2025 European Respiratory Society (ERS) Congress, BMC introduced a range of groundbreaking digital health innovations. Among the highlights were the G3 BPAP/CPAP series and the PAP Link system—solutions that attracted significant interest from healthcare professionals and media alike. These products aim to address one of Europe’s most pressing healthcare challenges: managing obstructive sleep apnea (OSA) and improving therapy adherence.

ERS 2025 and Key Trends in European Respiratory Care

The ERS Congress is the leading European conference dedicated to pulmonary and sleep health. The 2025 event placed a strong emphasis on chronic disease management and digital health solutions, with sleep apnea emerging as a core topic.

Recent studies indicate that in Germany, approximately 30% of men and 13% of women suffer from moderate to severe sleep apnea. This equates to millions of individuals experiencing poor sleep quality, daytime fatigue, and elevated health risks. The resulting strain on healthcare systems is significant—overburdened hospitals and rising insurance expenditures underscore the urgent need for innovative solutions.

In this context, digital tools that support therapy monitoring and adherence management are increasingly viewed as essential components of modern care. ERS 2025 provided BMC with an ideal platform to showcase how its solutions are already addressing these challenges effectively.

Market Challenges in Germany

Germany illustrates the scale of the issue: despite well-established health insurance frameworks, OSA remains widely under-treated, and therapy discontinuation rates remain high—particularly within the first year. Poor adherence results in frequent hospital visits and escalating treatment costs.

Insurers face additional hurdles, often requiring proof of device usage before approving reimbursement. Inadequate or unclear usage data can trigger therapy discontinuation, perpetuating a cycle of low adherence, rising costs, and patient frustration.

The solution requires a three-pronged approach:

• Patients need therapy that is comfortable, effective, and easy to use.

• Clinics need remote-monitoring capabilities to reduce the need for in-person follow-ups.

• Payers need clear, reliable usage data to validate treatment efficacy.

BMC Solutions: Smart, Connected Therapy for Modern Sleep Medicine

BMC addresses these challenges with two seamlessly integrated solutions designed to enhance patient comfort, clinical efficiency, and compliance tracking:

1. G3 A20 BPAP/CPAP – Smart, Adaptive Respiratory Therapy

The G3 A20 series represents the latest generation of intelligent PAP (Positive Airway Pressure) devices. Engineered to deliver precise, personalized therapy, it incorporates advanced detection and control technologies:

• Accurate Event Detection: Identifies central and obstructive apneas, hypopneas, and Cheyne-Stokes respiration with 100% accuracy under simulated test conditions.

• Dynamic Pressure Control: Responds rapidly and selectively to obstructive events, avoiding unnecessary pressure increases during central events.

• Intelligent Pressure Algorithm: Calculates optimal starting pressure based on the past five days of effective therapy data.

• Customizable Pressure Profiles: Offers three tailored modes (Fast, Standard, Soft) to accommodate varying severity levels and patient sensitivities—ideal for women and pressure-sensitive individuals.

• Extended Humidification: A 360 ml water chamber provides up to 10 hours of consistent humidification.

• User-Friendly Operation: Features auto start/stop, a ramp function, and a post-therapy drying mode for ease of use.

Key Benefits:
The G3 A20 helps reduce dropout rates, improve sleep quality, and lower the need for follow-up care—validated by independent bench testing conducted by KerNel Biomedical in 2025.

2. PAP Link – Secure, Cloud-Based Therapy Monitoring

PAP Link is an integrated digital health platform (available via web, mobile app, and PC) that supports real-time monitoring, remote device management, and comprehensive reporting. It connects all stakeholders—physicians, patients, pharmacies, and payers—within a secure, privacy-compliant ecosystem.

• Automatic Data Upload: Therapy data is transmitted to the cloud within 15 minutes after each session via Wi-Fi or cellular module.

• Remote Access for Clinicians: Physicians can adjust device settings, review therapy data, and intervene remotely—minimizing the need for in-person visits.

• Comprehensive Dashboards and Reports: Includes usage compliance, statistical summaries, and detailed session logs to support clinical decisions and reimbursement processes.

• Secure and Compliant: User-friendly interface, fully GDPR and HDS-compliant, with European-based hosting (data centers in France).

System-Level Benefits:
PAP Link demonstrably improves therapy adherence, reduces discontinuation rates, and facilitates more efficient, data-driven care while maintaining high standards of patient data privacy.

Integrated Platform for Better Clinical Outcomes

Together, the G3 A20 device and PAP Link platform form a powerful, cohesive solution that combines personalized therapy with robust digital oversight. This synergy enables:

• Actionable Adherence Insights: Real-time data enables timely interventions, boosting treatment success rates.

• Streamlined Clinical Workflows: Reduces administrative burden and follow-up requirements for healthcare providers.

• Reliable Documentation for Insurers: Ensures transparent, audit-ready records of therapy compliance.

Real-Time Support Builds Trust

With immediate support capabilities, healthcare professionals can proactively respond to therapy issues—reducing dropout risk and enhancing patient confidence. Clinicians benefit from time savings, while insurers gain reliable, data-driven documentation for reimbursement and oversight.

The Role of Pharmacies in the Care Ecosystem

Pharmacies are fully integrated into the PAP Link ecosystem, offering patients guidance, product education, and ongoing support. This multi-point engagement improves adherence and ensures a smoother therapy experience.

The result is a coordinated care model:

• Physicians prescribe,

• Pharmacists educate and support,

• Insurers fund the therapy,

• Patients remain engaged and compliant.

BMC enables this connected network, creating an ecosystem in which all participants benefit.

Compliance, Certification, and Safety

The G3 BPAP/CPAP device is CE-certified, meeting all relevant European safety and performance standards for medical devices. This ensures trust and reliability among clinicians, insurers, and patients alike.

Used exclusively under medical prescription, the device guarantees controlled clinical oversight. BMC also provides healthcare professionals and regulatory bodies with comprehensive technical documentation—reinforcing transparency and accountability.

These practices underscore BMC’s core commitment: delivering safe, responsible, and patient-centric care.

Conclusion

Obstructive sleep apnea remains a prevalent and costly health issue—too often left untreated. With the G3 A20 device and PAP Link platform, BMC offers an effective, user-friendly, and digitally integrated solution.

Together, they form a powerful duo that not only improves therapy outcomes but also fosters greater trust and transparency between patients, clinicians, and insurers.

At the ERS Congress 2025, BMC made clear its ambition to lead the way in connected, patient-focused sleep medicine.